Diagenode secures € 7.5 million in financing
Liege, Belgium: 20 June 2016 - Diagenode, a high growth, innovative life sciences company that focuses in epigenetics and molecular diagnostics, announced today that it has secured € 7.5 million in financing. The additional capital includes an equity component provided by Epimède SA, SRIW SA, OBI SA and the Capricorn Health-tech Fund NV (CHF, Leuven, Belgium) which is managed by Capricorn Venture Partners NV combined with a loan facility provided by SRIW, OBI and SpinVenture.
Diagenode was founded by Didier Allaer in 2003 and has quickly established a significant presence in the life sciences tools industry. Diagenode is now a leading provider of complete solutions for epigenetics research, offering innovative shearing and automation instruments, reagent kits, and high quality antibodies to streamline sample preparation workflows.
The company has also achieved significant growth in the diagnostics market. Diagenode develops and commercializes CE marked qPCR-based IVD kits for clinical biology laboratories for respiratory, gastric, and urinary infectious diseases. The kits have been developed both through proprietary means as well as through partnerships with major diagnostic companies.
More info on Diagenode's website.
Next > Nexstim Plc Key Technology Patent Granted in US
Previous > Mainstay Medical announces € 30 million fundraising